Titan Pharmaceuticals (TTP) Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer
2/13/2012 6:39:13 AM
JERUSALEM--(BUSINESS WIRE)--Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.
Following an approval by the Israeli Ministry of Health, Tiltan Pharma has launched the Phase 2 study in major oncology centers in Israel: The Tel Aviv Sourasky Medical Center, Hadassah Medical Center and the Sheba Medical Center at Tel-Hashomer. The clinical trial will enroll 80 patients with newly diagnosed metastatic pancreatic cancer that have not yet been treated with chemotherapy.